MIT Researchers Develop Harmless Virus Platform for Personalized Cancer Vaccines

·by Henderson·Engineering
MIT Researchers Develop Harmless Virus Platform for Personalized Cancer Vaccines
Key Points
  • MIT has developed a harmless virus as a cancer vaccine delivery platform.
  • Adjusting antigen concentration can enhance the vaccine's immune response efficacy.
  • The M13 virus can serve as an adjuvant for its own vaccine, boosting immune response.
  • This platform can be designed for personalized vaccines targeting different tumors.

Researchers at the Massachusetts Institute of Technology (MIT) have engineered a harmless virus into a nanoscale delivery platform aimed at aiding the development of personalized cancer vaccines. By controlling the display density of cancer-targeting proteins on the virus, the vaccine particles developed by the team significantly reduced tumor development in mice. The platform utilizes a modified bacteriophage known as M13, which infects bacteria but is harmless to humans. It forms long, thread-like structures called nanofibers that can cover antigens, helping the immune system recognize specific target proteins.

The researchers found that adjusting the concentration of these antigens on the viral structure altered the vaccine's ability to elicit an immune response. This could enable scientists to customize the particles based on the tumors of different patients.

The study was led by researchers at the Koch Institute for Integrative Cancer Research at MIT. Professor Angela Belcher, from Biological Engineering and Materials Science and Engineering, is the lead author, while research scientist Shengnan Huang is responsible for the execution of the work.

Adjusting Antigens to Enhance Immune Response

The M13 bacteriophage consists of a single-stranded DNA and a protein shell (capsid) surrounding it. The researchers modified a capsid protein known as pVIII by incorporating the corresponding genetic instructions into the virus to attach cancer antigens to its surface. However, controlling the number of antigen-carrying proteins on the viral structure is crucial. The researchers found that adding one or two negatively charged amino acids to the pVIII protein can increase the density of the antigens. They could also further adjust the yield of antigens by introducing genetic mutations that slow down antigen production.

Using these techniques, the team produced particles displaying a model antigen, SIINFEKL, with antigen densities ranging from 6% to 70%. In mouse experiments, the vaccine with an antigen density of 35% provided better protection than the vaccine with an antigen density of 6%. Mice that received the high-density vaccine were less likely to develop tumors after exposure to melanoma cells carrying the same antigen and produced more T cells targeting cancer-related proteins.

The researchers found that dendritic cells, which help activate T cells, were more likely to take up particles displaying higher antigen densities. The team also tested the platform using ADPGK, a neoantigen specific to colon tumors in mouse models. Neoantigens are proteins produced by changes in cancer cells that help the immune system distinguish tumors from healthy tissue. Mice receiving the high-density vaccine showed a significantly reduced likelihood of developing colon tumors, indicating that the platform can be tailored to target different cancer-specific proteins.

Adjuvant Properties of the M13 Virus

Another feature of the system is that the M13 virus can act as its own vaccine adjuvant, a substance that enhances the immune response. Its single-stranded DNA activates a pathway known as TLR9, which helps stimulate the body's innate immune system. By modifying the genetic sequence of the virus, researchers can also control the activity of this adjuvant. This may eliminate the need to add separate immune-stimulating components to the vaccine.

Modular Design Supports Personalized Vaccines

The modular design of the platform means that researchers can replace one antigen with another to target different types of tumors. This could ultimately support vaccines tailored to the specific molecular characteristics of individual patients' cancers. These findings build on the team's earlier research, which explored using M13-based nanovaccines to treat established tumors in mice. However, in the latest study, researchers primarily tested the vaccine's ability to prevent tumor development. This approach remains in preclinical research stages, with further studies needed to determine whether it can safely and effectively treat diagnosed cancers and whether the results can be translated to human applications.

The study was published in the journal Advanced Healthcare Materials.

Prospects and Challenges of Personalized Cancer Vaccines

This research demonstrates the potential of utilizing a harmless virus platform to develop personalized cancer vaccines. By adjusting antigen concentrations, researchers were able to enhance the immune response of the vaccine, which is crucial for targeting the tumor characteristics of different patients. Additionally, the M13 virus's properties as its own vaccine adjuvant may simplify the vaccine design process and reduce reliance on external immune components. However, this approach is still in preclinical research stages, and further exploration is needed regarding its safety and efficacy in clinical applications.

H
About the author
Henderson